Versant gambles $20 million on a UCSD spinout focused on NASH and fibrosis
Back in the spring of 2015, Jeffrey Stafford helped set up a deal with Celgene to acquire the drug discovery platform he helped create …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
